Boehringer Ingelheim Selects ACD/Labs for International Deployment
Product News Dec 01, 2016
ACD/Labs has announced that Boehringer Ingelheim, a leading pharmaceutical company, chose to deploy ACD/NMR Workbook Suite and ACD/NMR Predictors to NMR spectroscopists as well as ACD/Spectrus Processor to several hundred scientists, in Europe and North America.
“It was attractive to our user base to access functionality lacking in instrument vendor software and static pdf reports such as prediction of spectra from structure; assignment of peaks to structure; visualization of data; and interactivity to review and reanalyze data to research features that were not of interest when the analysis was first done,” says Paul-James Jones—IT Business Consultant, Boehringer Ingelheim and Allotrope project representative. “The move to a wider deployment of ACD/Labs tools provided simplification of our application landscape, helping us operate more efficiently from an IT perspective.”
An Allotrope Foundation partner, ACD/Labs shares the vision of standardized analytical data pursued by the Foundation and by Boehringer Ingelheim. ACD/Labs’ unique expertise in vendor agnostic analytical data processing and management has made them the ‘go-to’ provider for two decades.
“The fragmentation and siloing of analytical data is a problem that we help our customers address by supporting unification in a single, searchable software environment,” says Gabriela Cimpan—Director of European Sales, ACD/Labs. “We enable our customer organizations to extract maximum value from their investment in analytical data by storing human interpretations of data and helping them retain analytical intelligence. While this deployment of software is focused on supporting NMR spectroscopy, we look forward to working with Boehringer Ingelheim to extend their use of our portfolio to other techniques in the future”